Moleculin Biotech, Inc. (0K2H)
LSE
0.5500
-0.09 (-13.67%)
Closed
Sep 28, 2026
Day's Range
0.53640.6040
52 wk Range
0.240517.27
Financial Statements - 0K2H - Moleculin Biotech, Inc.
Revenue
106.42M▲ 21.9%
Net Income
4.66M▲ 53.9%Net Margin 4.4%
EBITDA
12.24M▲ 21.6%
Free Cash Flow
8.70M▼ 38.8%
Income Statement
| Period Ending | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|
| Sales | 106.42M | 87.30M | 81.78M | 82.99M |
| Cost of Goods | 76.94M | 61.21M | 56.98M | 58.95M |
| Gross Profit | 29.47M | 26.09M | 24.80M | 24.04M |
 Operating Expense | - | - | - | - |
| Operating Income | 6.65M | 4.62M | 2.11M | 2.57M |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | - | - | - | - |
| Pre Tax Income | 5.99M | 4.25M | 1.82M | 2.30M |
| Income Tax | 1.33M | -390K | 562K | 585K |
| Net Income | 4.66M | 3.03M | 1.26M | 1.71M |
| EPS Basic | 0.33 | 0.23 | 0.097249 | 0.126423 |
| EPS Diluted | 0.32 | 0.22 | 0.097249 | 0.126423 |
| Basic Shares Outstanding | 13.60M | 13.24M | 13.24M | 13.11M |
| Diluted Shares Outstanding | 13.60M | 13.24M | 13.24M | 13.11M |
| Ebit | - | - | - | - |
| Ebitda | 12.24M | 10.06M | 7.56M | 3.50M |
| Net Income Continuous Operations | 6.46M | 4.06M | 2.06M | 2.41M |
| Minority Interests | -210K | - | - | 0 |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
